Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States-Reference-Cited by-同舟云学术

Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States

Published:2018-10-02 Issue:4 Volume:60 Page:955-963
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Goyal Ravi K.¹,Nagar Saurabh P.¹,Kabadi Shaum M.²,Kaye James A.³,Seal Brian²,Mato Anthony R.⁴

Affiliation:

1. RTI Health Solutions, Research Triangle Park, NC, USA;

2. AstraZeneca, Gaithersburg, MD, USA;

3. RTI Health Solutions, Waltham, MA, USA;

4. Department of Medicine, Division of Hematological Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Funder

AstraZeneca

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1509320

Reference30 articles.

1. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004

2. Clinical behavior and treatment outcome of primary nasal diffuse large B-cell lymphoma

3. Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry

4. Leukemia and Lymphoma Society. Mantle cell lymphoma facts. 2014 [cited 2018 Jan 12]. Available from: https://www.lls.org/sites/default/files/file_assets/mantlecelllymphoma.pdf

5. Current and emerging treatment options for mantle cell lymphoma

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis;Clinical Lymphoma Myeloma and Leukemia;2024-06

2. Real-world treatment patterns, healthcare resource utilization and total cost of care in mantle cell lymphoma from US commercial claims;International Journal of Hematologic Oncology;2023-12-31

3. Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs;Leukemia & Lymphoma;2023-07-27

4. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis;Expert Review of Pharmacoeconomics & Outcomes Research;2023-06-06

5. Tackling Mantle Cell Lymphoma in Europe;Healthcare;2022-09-03